Program
belzutifan
Also written as “Belzutifan” and “Belzutifan 120mg”.
Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · von Hippel-Lindau Disease · Pheochromocytoma · Breast Neoplasms, led by Merck.
Drug pageBelzutifan: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 2415 open or running | phase 3since Dec 10, 2019 | Aug 3, 2016 | Feb 26, 2027phase 2 · NCT03634540 |
Also a collaborator on its studies: Eisai.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, Aug 3, 2016 to Jul 27, 2020.
- Dec 9, 2019Named belzutifanINNProposed as its International Nonproprietary Name in WHO's List 122
- Oct 9, 2020Phase 3 study in Carcinoma, Renal CellNCT04586231 · 747 enrolled · United States, Argentina, Australia and more
- Nov 10, 20202 phase 2 studies in Carcinoma, Renal CellNCT04626518, NCT04626479
- Jan 29, 2021Phase 3 study in Carcinoma, Renal CellNCT04736706 · 1,688 enrolled · United States, Australia, Brazil and more
- Apr 7, 2021Phase 1 study in Carcinoma, Renal CellNCT04846920 · 29 enrolled · United States
- Jun 8, 2021Phase 2 study in PheochromocytomaNCT04924075 · 355 planned · United States, Australia, Canada and more
- Jul 16, 2021Phase 2 study in NeoplasmsNCT04976634 · 730 enrolled · United States, Australia, Belgium and more
- Aug 2, 20213 phase 1 studiesNCT04995484, NCT04994522, NCT05030506
- Feb 4, 2022Phase 3 study in Carcinoma, Renal CellNCT05239728 · 1,800 enrolled · United States, Australia, Brazil and more
- Jun 2, 2023Phase 3 study in Carcinoma, Renal CellNCT05899049 · 251 enrolled · China
- May 20, 2024Phase 2 study in Breast NeoplasmsNCT06428396 · 120 enrolled · United States, Argentina, Canada and more
- Mar 25, 2025Phase 1 study in HealthyNCT06903715 · 14 enrolled · United States
- Aug 12, 2025Phase 1 study in HealthyNCT07121959 · 14 enrolled · United States
- Feb 5, 2026Phase 3 study in von Hippel-Lindau DiseaseNCT07405164 · 450 planned · United States, Australia, Belgium and more
- Jul 8, 2026Phase 2 study in NeoplasmsNCT07700758 · 15 planned · United States, Belgium, Denmark and more
Ahead
- Feb 26, 2027Primary completion: phase 2 study in Carcinoma, Renal CellNCT03634540
- Mar 22, 2027Primary completion: phase 2 study in NeoplasmsNCT04976634
- Apr 29, 2027Primary completion: phase 2 study in von Hippel-Lindau DiseaseNCT03401788
- May 5, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06428396
TargetBeta
“Endothelial PAS domain-containing protein 1 inhibitor”ChEMBL 37, by rule
Other programs on EPAS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| casdatifanrule | Arcus Biosciences | phase 3 | 9 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700758Neoplasms · United States, Belgium, Denmark and more | 2 | Recruiting | Jan 2, 2034 | 15 |
| NCT07405164von Hippel-Lindau Disease · United States, Australia, Belgium and more | 3 | Recruiting | Apr 22, 2034 | 450 |
| NCT07121959Healthy · United States | 1 | Completed | Sep 13, 2025 | 14 |
| NCT06903715Healthy · United States | 1 | Completed | May 8, 2025 | 14 |
| NCT06428396Breast Neoplasms · United States, Argentina, Canada and more | 2 | Active, not recruiting | May 5, 2027 | 120 |
| NCT05899049Carcinoma, Renal Cell · China | 3 | Active, not recruiting | Feb 4, 2026 | 251 |
| NCT05239728Carcinoma, Renal Cell · United States, Australia, Brazil and more | 3 | Active, not recruiting | Oct 28, 2026 | 1,800 |
| NCT05030506Carcinoma, Renal Cell · China | 1 | Active, not recruiting | Jun 30, 2027 | 45 |
| NCT04995484Moderate Hepatic Impairment · United States | 1 | Completed | Dec 25, 2023 | 17 |
| NCT04994522Kidney Failure, Chronic · United States | 1 | Completed | Apr 1, 2024 | 14 |
| NCT04976634Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 22, 2027 | 730 |
| NCT04924075Pheochromocytoma · United States, Australia, Canada and more | 2 | Recruiting | Nov 18, 2032 | 355 |
| NCT04846920Carcinoma, Renal Cell · United States | 1 | Completed | Apr 11, 2026 | 29 |
| NCT04736706Carcinoma, Renal Cell · United States, Australia, Brazil and more | 3 | Active, not recruiting | Feb 4, 2026 | 1,688 |
| NCT04626518Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Jul 23, 2026 | 263 |
| NCT04626479Carcinoma, Renal Cell · United States, Australia, Canada and more | 2 | Completed | Aug 10, 2026 | 393 |
| NCT04586231Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2, 2026 | 747 |
| NCT04489771Carcinoma, Renal Cell · United States, Australia, Belgium and more | 2 | Completed | Feb 10, 2023 | 154 |
| NCT04195750Carcinoma, Renal Cell · United States, Brazil, Canada and more | 3 | Active, not recruiting | Apr 15, 2024 | 755 |
| NCT03634540Carcinoma, Renal Cell · United States | 2 | Active, not recruiting | Feb 26, 2027 | 118 |
| NCT03445169Healthy · United States | 1 | Completed | May 26, 2018 | 16 |
| NCT03401788von Hippel-Lindau Disease · United States, Denmark, France and more | 2 | Active, not recruiting | Apr 29, 2027 | 50 |
| NCT02974738Carcinoma, Renal Cell | 1 | Active, not recruiting | Jan 12, 2018 | 120 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Oct 22, 2027 | 1,200 |
How it is read
Names in the registry
- “Belzutifan”, 23 entries
- “Belzutifan 120mg”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 12 studies
- Neoplasms, 2 studies
- von Hippel-Lindau Disease, 2 studies
- Pheochromocytoma, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.